VABC Responds to Study on Use of Cholesterol Lowering Drug Statins on Cancer Patients
Voices Against Brain Cancer replies to an article published by NBC News regarding a new study which claims that cancer patients who took the drug were less likely to pass away than those who did not.
New York, NY (PRWEB) December 08, 2012
On December 8, Voices Against Brain Cancer (VABC) releases a statement in reaction to the results of a new study on taking a cholesterol lowering drug that reduces the death risk in cancer patients.
According to an article on NBC News, “the patients who took statins were about 15 percent less likely to die from their cancer than other cancer patients were, the researchers reported after studying the records of nearly 300,000 people.”
The article affirms that the research is not conclusive since it was only based on studies of past medical records, and further research would be needed to prove that statins do reduce the risk of death in cancer patients. However, according to the article, “studies have shown that by blocking cholesterol production and certain protein interactions in cells, statins may influence the ability of cells to proliferate and migrate through the body. So statins could be reducing the ability of cancer cells to metastasize.”
In reaction to these findings, VABC representative Clay Darrohn stated, “We would definitely like to see more in-depth research of these findings. If conclusive, these studies could be very exciting for further brain cancer research.”
VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization´s research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, to name a few.
VABC’s mission is to find a cure for brain cancer by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers afflicted with this devastating disease.
For press inquiries, please contact: 5W Public Relations.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/12/prweb10211128.htm